Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

Molecular profiling results are used to assign targeted therapy. Patients receive targeted therapy by participating in a Phase I or a Phase II clinical trial. If a clinical trial is not available, and a commercially available targeted therapy exists (Food and Drug Administration \[FDA\]-approved for another indication), patients can receive the FDA-approved drug.

Standard-of-care treatment regimen will be left to the discretion of the treating physician.